Improved quantification of protein in vaccines containing aluminum hydroxide by simple modification of the Lowry method  by Lee, Naery et al.
BI
h
N
H
a
C
b
a
A
R
R
A
A
K
P
L
I
A
V
N
1
E
t
t
v
l
d
s
(
r
i
m
e
c
c
a
a
b
h
0
nVaccine 33 (2015) 5031–5034
Contents lists available at ScienceDirect
Vaccine
j our na l ho me page: www.elsev ier .com/ locate /vacc ine
rief  report
mproved  quantiﬁcation  of  protein  in  vaccines  containing  aluminum
ydroxide  by  simple  modiﬁcation  of  the  Lowry  method
aery  Leea,b,  SukJin  Shina, Hye  Joo  Chunga, Do  Keun  Kima, Jong-mi  Lima,
yunsung  Parkb, Ho  Jung  Oha,∗
Vaccines Division, National Institute of Food and Drug Safety Evaluation, 187 Osongsaengmyeoung 2-ro, Osong-eup, Heungdoek-gu, Cheongju-si 28159,
hungcheongbuk-do, Republic of Korea
Department of Life Science, University of Seoul, Siripdae-gil 13, Dongdaemun-gu, Seoul, Republic of Korea
 r  t  i  c  l  e  i  n  f  o
rticle history:
eceived 22 June 2015
eceived in revised form 29 July 2015
ccepted 2 August 2015
vailable online 12 August 2015
eywords:
a  b  s  t  r  a  c  t
Aluminum  (Al) components  in  vaccines  are  known  to  act as adsorbents  that interfere  with  accurate
protein  quantiﬁcation  by  the  Lowry  method.  Therefore,  certain  modiﬁcations  based  on  the  characteristics
and  compositions  of  the  vaccine  are  required  for  determination  of protein  contents.
We  investigated  the  effects  of  an  additional  centrifugal  separation  and  found  that  protein  contents
were  overestimated  by  up  to 238%  without  centrifugation  through  a collaborative  study  performed  with
hepatitis  B vaccines  containing  Al.  However,  addition  of  a centrifugation  step  yielded  protein  concentra-rotein quantiﬁcation
owry method
nterference
luminum
accine
tions  that  were  similar  to the  actual  values,  with  small  coefﬁcients  of  variation  (CVs).  Proﬁciency  testing
performed  in  11 laboratories  showed  that  four  laboratories  did  not  have  satisfactory  results  for vaccines
containing  aluminum  hydroxide,  although  all laboratories  were  proﬁcient  in  protein  analysis  when  sam-
ples  did  not  contain  aluminum  hydroxide.  Incomplete  resuspension  of  aluminum  hydroxide  solution
with  alkaline  copper  solution  was  the  major  cause  of  insufﬁcient  proﬁciency  in these  laboratories.
ublisational lot release © 2015  The  Authors.  P
. Introduction
According to Korean regulations, U.S. Pharmacopoeia [1], and
uropean Pharmacopoeia [2], the Lowry method is thought to be
he most accurate method for determining the protein concentra-
ions of licensed vaccines. However, various substances used for
accine production, such as sucrose, Triton X-100, EDTA, Tris–HCl,
actose, and amino acid derivatives, may  interfere with protein
eterminations [3–10]. Therefore, several modiﬁcations, including
uch as sodium deoxycholate (DOC) treatment, trichloroacetic acid
TCA) precipitation, or heat treatment, have been investigated for
emoval of interfering substances [5–9]; these modiﬁcations are
ncluded in the method referred to as the “conventional Lowry
ethod.” Unfortunately, these techniques are not effective for
liminating the interference of aluminum hydroxide [Al(OH)3], a
ommonly used adsorbent in vaccine production. Moreover, while
Abbreviations: Al, aluminum; CV, coefﬁcient of variation; DOC, sodium deoxy-
holate; TCA, trichloroacetic acid; Al(OH)3, aluminum hydroxide; DAFIA, direct
lhydrogel formulation immunoassay; OPA, O-phthalaldehyde; SOP, standard oper-
tive procedure; NIFDS, National Institute of Food and Drug Safety Evaluation; BSA,
ovine serum albumin; IQR, interquartile range; ANOVA, analysis of variance.
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d/4.0/).hed  by  Elsevier  Ltd. This  is an  open  access  article  under  the CC  BY-NC-ND
license  (http://creativecommons.org/licenses/by-nc-nd/4.0/).
direct alhydrogel formulation immunoassays (DAFIAs) [11] or O-
phthalaldehyde (OPA) assays [12] have been used for minimization
of aluminum interference, these methods do not satisfy quality
control standards due to insufﬁcient sensitivity, poor reproducibil-
ity, and challenges with the preparation of antigens speciﬁc to the
target proteins.
Prior to the initiation of this study, we reviewed the standard
operating procedures (SOPs) of the Lowry method used by vac-
cine manufacturers and vaccine quality testing institutions. Several
laboratories used only the conventional Lowry method to test
vaccines containing Al(OH)3, without the interference removal
step. Therefore, we  designed an Al-adjusted Lowry method for
protein quantiﬁcation of vaccines containing Al(OH)3 by adding
a centrifugation step to the conventional Lowry method. We
then performed collaborative and proﬁciency studies and pro-
posed a methodological adjustment for overcoming Al(OH)3
interference.
2. Materials and methods2.1. Reference standard for protein quantiﬁcation
Pierce Bovine Serum Albumin (BSA) Standard (cat no. 23209;
Thermo Fisher Scientiﬁc Inc.) was used as a reference standard.
nder the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-
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Fig. 1. Veriﬁcation of the accuracy of the Al-adjusted Lowry method. (A) Three BSA concentrations (12.5 [], 25 [], and 50 [] g/mL) were diluted with distilled water
and  placebo solution. Assays were performed independently on three different days. Each data point represents the mean ± standard deviation. (B) Three vaccine man-
ufacturers and NIFDS performed protein quantiﬁcation using Euvax-B Inj. as a sample containing Al in a collaborative study. To assess the effects of application of a
centrifugal separation step, two values from samples subjected to centrifugal separation () or not () are presented. (C) Identical assays were performed using Hepavax-Gene
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.2. Placebo solution
Placebo solution containing buffers, isotonic agents, and
l(OH)3, but not hepatitis B antigen, was obtained from a hepatitis
 vaccine manufacturing company to conﬁrm the interference of
l(OH)3 on protein quantiﬁcation.
.3. Protein quantiﬁcation by the Al-adjusted Lowry method
BSA was diluted serially to concentrations ranging from 5 to
00 g/mL. Each standard solution and sample were mixed with
0% TCA and immersed in boiling water for 15 min. After cool-
ng at room temperature and centrifugation at 3700 × g for 20 min,
he precipitate was resuspended by adding 5% TCA solution fol-
owed by centrifugation at 3700 × g for 20 min, and the supernatant
as then removed. The precipitate was resuspended by addi-
ion of alkaline copper solution. The diluted phenol reagent was
hen added, and the precipitate solution was incubated for 30 min
t 37 ◦C.For samples containing Al(OH)3, an additional centrifugation
tep at 2000 × g for 5 min  was included for separating interfering
aterial. The supernatant was then collected, and the absorbance
as measured at 750 nm.2.4. Comparison of BSA quantiﬁcation in distilled water and
placebo solution
BSA was diluted with distilled water and placebo solution to
12.5, 25, or 50 g/mL; thus, the test represented the target protein
concentration of approximately 20 g/mL, which is used for hep-
atitis B vaccine production. We  performed the protein assay using
conventional and Al-adjusted Lowry methods and compared the
results.
2.5. Collaborative study
A collaborative study was  performed using vaccines containing
Al(OH)3, Euvax-B Inj. (LG Life Sciences Ltd.) and Hepavax-Gene TF
(Berna Biotech Korea Corp.), by the conventional and Al-adjusted
Lowry methods. Three domestic vaccine manufacturers and the
NIFDS participated, and all laboratories conducted separate assays
based on a controlled protocol.
2.6. Proﬁciency testingEight vaccine manufacturers, two  vaccine quality testing institu-
tions, and the NIFDS participated using samples without Al (Korean
National Biological Reference Standard for Japanese Encephalitis
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Fig. 2. Proﬁciency testing to assess the performance of laboratories using samples with or without Al. Proﬁciency testing was performed using test solutions without Al (Korean
National Biological Reference Standard for Japanese Encephalitis vaccine, second inj., code 07/022) or with Al (Korean National Biological Reference Standard for Adsorbed
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liphtheria Toxoid, code 03/013). (A): z-scores, 07/022; (B): robust z-scores, 07/0
ptimization, 03/013, (F): robust z-scores after test method optimization, 03/013.
accine, code 07/022) or with Al(OH)3 (Korean National Biological
eference Standard for Adsorbed Diphtheria Toxoid, code 03/013).
or proﬁciency assessment, the z-score and robust z-score were
sed to calculate the relative distance of the results for each labo-
atory in relation to the assigned value.
.7. Data analysis
.7.1. Proﬁciency testing: z-Scores
Laboratory performance was measured by the z-score, which
s a comparison-based score relative to other laboratories par-
icipating in the proﬁciency testing. The closer the z-score of a
aboratory was to zero, the higher the agreement of its performance
as with those of other laboratories. Testing criteria are shown
elow.
Performance estimation method Performance level criteria
z = (x − X)/s |z| ≤ 2: satisfactory
2 < |z| < 3: average,
permissible
|z| ≥ 3: unsatisfactory
here x is the measured value of a laboratory; X is the mean of all
aboratories; s is the dispersion of resulting values.): z-scores, 03/013, (D): robust z-scores, 03/013, (E): z-scores after test method
2.7.2. Proﬁciency testing: Robust z-scores
Robust z-score is a rating scheme used for minimizing the
impact of outliers on the mean or standard deviation of the esti-
mated values. In this calculation, x is the measured value of a
participating laboratory, X is the median value of all participating
laboratories, and s is the normalized interquartile range (IQR) rep-
resenting the dispersion of the resulting values. The performance
estimation method and performance level criteria were the same
as the rating used for the z-score.
2.7.3. Statistical analysis
Differences in test results among the laboratories in proﬁ-
ciency testing were determined using one-way analysis of variance
(ANOVA) with p-values and F-ratios. Shapiro–Wilk W analysis was
also performed to conﬁrm the normal distribution with the p-
values obtained from proﬁciency testing. If the p-values were over
0.05, the data distribution could not reject normality with 95% con-
ﬁdence level.
3. Results and discussionThe protein contents of BSA diluted with placebo solution were
assayed with the conventional Lowry method and compared with
corresponding concentrations measured using the Al-adjusted
5 ne 33 (2015) 5031–5034
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of a direct alhydrogel formulation immunoassay (DAFIA). J Immunol Methods034 N. Lee et al. / Vacci
owry method. BSA contents (12.5, 25, and 50 g/mL) were overes-
imated by 50%, 27%, and 18%, respectively, using the conventional
owry method compared with results using the Al-adjusted Lowry
ethod (Fig. 1A). However, when BSA was diluted with distilled
ater, the difference of results between the two  Lowry methods
as within 3%.
Next, we examined the effects of centrifugal separation in a
ollaborative study using Euvax-B Inj. and Hepavax-Gene TF Inj.
he means and CVs of protein contents with and without centrifu-
al separation were 22 g/mL and 11% versus 42 g/mL and 31%,
espectively, for Euvax-B Inj. (Fig. 1B) and 19 g/mL and 12% versus
8 g/mL and 35%, respectively, for Hepavax-Gene TF Inj. (Fig. 1C).
he results determined by the Al-adjusted Lowry method were
lose to the target protein concentration, and the ranges of the over-
stimation ratios without the centrifugation step were 43–167% for
uvax-B Inj. and 50–238% for Hepavax-Gene TF Inj. Moreover, the
eproducibility of the conventional Lowry method based on CVs
as three times more than that of assays by the Al-adjusted Lowry
ethod.
The results of the proﬁciency testing showed that nine labora-
ories reached ‘satisfactory’, and two laboratories (4 and 5) showed
average’ performance (Fig. 2A and B). If the results were consid-
red to have a normal distribution, the z-score and robust z-score
ielded similar patterns. Otherwise, using the robust z-score could
ompensate for the effects of extreme values. The results of the
hapiro–Wilk W test indicated a normal distribution, and there
ere no obvious differences between the z-score and robust z-
core (Fig. 2A and B). Based on the previous data, we  informed the
aboratories that they should include an additional centrifugation
tep in their SOPs for samples containing Al(OH)3. After collecting
ata with samples containing Al(OH)3, we excluded the results
rom three laboratories for analysis because of practical errors.
ab 5 did centrifuge the samples before adding TCA, but instead
entrifuged just before measuring absorbance. Labs 6 and 10 spec-
lated that they performed insufﬁcient resuspension of the alkaline
opper solution. Proﬁciency testing revealed that seven labora-
ories achieved satisfactory results, and one laboratory obtained
verage results (Fig. 2C). In contrast, in the Shapiro–Wilk W test
ndicating that the results did not show a normal distribution
p = 0.025). Accordingly, we found that the absolute values of robust
-score indicated that Lab 8 had unsatisfactory results (approxi-
ately 6), suggesting a greater likelihood of errors in the test result
ompared with that in the other laboratories (Fig. 2D).
Consequently, four laboratories (Labs 5, 6, 10, and 8) carried out
he retest using the same samples containing Al(OH)3 by analyzing
he causes of these poor results. Reassessment results indicated that
ll laboratories satisﬁed the normal distribution (p = 0.572), and all
aboratories showed satisfactory or average results for both the z-
core and robust z-score (Fig. 2E and F). Thus, the critical problems
ere addressed by root cause analysis, and the practical errors were
xed.
The laboratories that carried out quality monitoring without a
entrifugal separation assumed that the Al gel would precipitate at
he bottom of the tube; thus, the measurement results would not
e greatly affected by Al particles. However, the reproducibility of
he tendency for overestimation could not be validated through
epeated experiments and was affected by the type of Al gel used
nd the proteins adsorbed. Moreover, Al only and Al phosphate
id not interfere with the Lowry method in our study (data not
hown). This implied that stirring the reaction to make a homo-
eneous placebo solution resulted in interference with protein
uantiﬁcation using the Lowry method. Thus, the National Control
[Fig. 3. Schematic showing a summary of the study.
Laboratory of Korea has begun to suggest inclusion of the cen-
trifugation for quality control of vaccines containing Al(OH)3. We
propose inserting this step globally for harmonization in case of
vaccines containing Al for accurate and reproducible results (Fig. 3).
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